Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-07-03 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
6K: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs
Regulatory Filings Classification · 95% confidence The document explicitly references '6K: Transaction documents' and is filed by a foreign private issuer, indicating it is an SEC Form 6-K filing. The text states, 'Attached hereto is a report on *6K: Transaction documents* *ea020886901-6k_purplebio_bannerless_isa.pdf*'. Since the document itself is an announcement stating that a report is attached, and it does not contain the full content of a comprehensive report (like an Annual Report or Interim Report), it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that 6-K filings are specific regulatory disclosures, and RPA is for announcing the publication of reports, RNS is the most appropriate general regulatory fallback when a specific code like 10-K or IR is not applicable, especially for non-US specific SEC filings that are being disseminated via local exchanges (like TASE). However, since the document is announcing a specific regulatory filing (6-K), and the definitions do not explicitly cover 6-K, RNS is the best fit as a general regulatory announcement.
2024-07-03 English
6K-Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Regulatory Filings Classification · 97% confidence The document is explicitly titled "FORM 6-K" and is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934". Form 6-K filings are used to report material information that a foreign private issuer is required to disclose to its home country exchange or shareholders. The content itself is a press release announcing the closing of a warrant exercise for cash proceeds, which is material information. While it contains an earnings-related announcement (financing/capital raise), the primary structure and filing mechanism is the Form 6-K. Among the provided codes, there is no specific code for Form 6-K. Form 6-K often contains material events that might fit under Capital/Financing Update (CAP) or Regulatory Filings (RNS). Since this is a specific, mandatory SEC filing type (Form 6-K) reporting a material event (financing), and it is not a full annual report (10-K), quarterly report (IR), or earnings release (ER) which typically use 20-F/6-K/10-Q, the most appropriate general category for a specific, non-standard SEC filing that doesn't fit the other detailed categories is the fallback, Regulatory Filings (RNS). However, given the content is a financing event (issuance of new warrants and proceeds), 'CAP' (Capital/Financing Update) is also highly relevant. Since the document *is* the filing itself (Form 6-K) reporting the financing, and not just an announcement of a report, I will prioritize the content type over the generic filing fallback if a content type fits well. The event is a capital raise/financing activity. Therefore, CAP is a strong candidate. If CAP is too specific for a 6-K, RNS is the fallback. Given the detailed description of warrant exercise and proceeds, CAP is the best fit for the *substance* of the filing, even though the *form* is 6-K.
2024-07-03 English
6K-Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4, referencing a '6K' filing structure, which is typical for foreign private issuers reporting material events to the SEC (though this specific filing seems to be routed through the Israel Securities Authority and TASE). The content announces the 'Closing of Exercise of Warrants for $2 Million Gross Proceeds'. Crucially, the text states: 'Attached hereto is a report on *6K: Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds* *ea020888701-6k_purplebio_bannerless_isa.pdf*'. Since the document itself is short (2155 chars) and primarily serves to announce the publication of an attached or linked report (the 6K/PDF), it fits the definition of a Report Publication Announcement (RPA) rather than the underlying financial report itself (like CAP or ER).
2024-07-03 English
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 6-K" and is filed by a "Foreign Private Issuer" with the SEC. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country, or that is otherwise material to investors. The content is a press release announcing the exercise of warrants for capital raising, which is a material event. Since Form 6-K is a general reporting requirement for foreign private issuers and doesn't map directly to the specific US periodic reports (like 10-K or 10-Q), it falls under the general category for miscellaneous regulatory filings that do not fit other specific definitions. The closest fit among the provided codes for a general, non-periodic regulatory filing that isn't a specific report type (like ER, IR, AR) or an announcement of a report (RPA) is 'Regulatory Filings' (RNS). The document is not a standard US periodic report, nor is it a specific announcement like a dividend, management change, or proxy statement. It is a formal SEC filing containing material news.
2024-07-01 English
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Report Publication Announcement Classification · 98% confidence The document is very short (2175 characters) and explicitly states, "Attached hereto is a report on*6K: Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds* ea020878501-6k_purpleEDGAR2_Bannerless_isa.pdf". This structure—an announcement referencing an attached or linked primary document (a 6-K filing, which is an 'Other Report' under SEC rules, but here it's being used as a wrapper)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notification of its release. The presence of the ISA/Tase headers suggests it is a regulatory filing wrapper, but the core function here is announcing the publication of the detailed report.
2024-07-01 English
Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
Regulatory Filings Classification · 99% confidence The document is explicitly titled "FORM 6-K" and is filed by a "Foreign Private Issuer" with the SEC. Form 6-K is used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country, or furnishes to the SEC. The content is a press release dated June 27, 2024, announcing interim clinical trial results for a drug (CM24) and providing details about the data and an upcoming KOL event. This structure—a Form 6-K incorporating a press release about clinical/business updates—is a common form of regulatory disclosure for foreign issuers. Since the document is a formal SEC filing (Form 6-K) containing material business information, it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were purely financial results. However, given the specific nature of the 6-K filing wrapper and the content being a detailed clinical update rather than just summary earnings figures, RNS (Regulatory Filings) is the most appropriate general category for non-standard SEC forms that convey material news, especially when the specific content doesn't map perfectly to 10-K, IR, or ER. Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' and Form 6-K is a miscellaneous regulatory filing, RNS is the best fit. The document length is substantial (17665 chars), so it is not an RPA.
2024-06-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.